X

ARA-290 / 16 mg

50,00 

ARA-290 16 mg is a synthetic erythropoietin-derived peptide supplied in lyophilized powder form for laboratory research. Commonly investigated in studies of tissue protection signaling and inflammatory pathway modulation. Delivered as a 16 mg sterile lyophilized preparation in a sealed research vial.

In stock

Category:

Description

Peptide for inflammation, pain modulation & tissue protection research

Product overview

ARA-290 (also known as Cibinetide) is a synthetic peptide derived from the erythropoietin (EPO) helix-B region. It is widely studied for its anti-inflammatory, cytoprotective, and pain-modulating properties without stimulating erythropoiesis. ARA-290 is of particular interest in research involving neuropathic pain, autoimmune conditions, and tissue repair.

Key benefits (anecdotal & research-based)

Investigated for reducing neuropathic pain and nerve inflammation.
Studied for autoimmune and inflammatory condition models.
May promote tissue protection without altering RBC production.
Potential regulatory effects on the innate repair receptor (IRR).
Interesting candidate in ischemia-reperfusion and nerve-regeneration studies.

Product characteristics

Purity: ≥98% (HPLC-tested)
Appearance: Lyophilized white/off-white powder
Molecular formula: C51H84N16O21
Molecular weight: 1257.31
Sequence: Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
Storage: store lyophilized powder at -20°C, protect from light and moisture. Reconstituted solution should be kept at 2–8°C and used within a short period.

Why choose our ARA-290?

≥ 98% purity verified by HPLC.
Produced in GMP-compliant facilities under strict QC protocols.
Each batch carefully lab tested after production (you can find Certificate of Analysis under product pictures).
Freeze-dried (lyophilized) for maximum stability and extended shelf life.
Sealed in sterile vials, ready for reconstitution.

Suggested use

In research settings, ARA-290 is most commonly studied through subcutaneous administration. Common protocols (based on anecdotal reports):
Typical research dosage: 2–4 mg per administration.
Protocol frequency: Daily or every other day depending on study design.
Must be reconstituted using appropriate laboratory technique. Due to its physicochemical properties, ARA-290 may require initial pre-solubilization with dilute acetic acid to achieve full dissolution before dilution with bacteriostatic water or buffered solutions. Inadequate pH conditions or improper handling may result in incomplete dissolution or a whitish/opalescent appearance.

NOTE: This is for educational reference only and does not constitute medical advice.

Disclaimer:
This product is sold for research purposes only. It is not intended to diagnose, treat, cure, or prevent any disease. Buyer assumes full responsibility for proper handling and use.

Reviews

There are no reviews yet.

Be the first to review “ARA-290 / 16 mg”

Your email address will not be published. Required fields are marked *

Related products